Immutep Limited (IMMP)

Immutep Limited (IMMP) Healthcare & Pipeline Overview

Immutep Limited, an Australian biotechnology firm, specializes in developing immunotherapeutic product candidates for cancer and autoimmune diseases. Its pipeline features eftilagimod alpha in Phase IIb for metastatic breast cancer, alongside other clinical-stage assets, leveraging strategic collaborations to advance novel treatments.

What Is the Investment Thesis for IMMP?

Immutep Limited presents a research-driven profile centered on its diverse immunotherapeutic pipeline, particularly eftilagimod alpha (efti), which is in advanced Phase IIb clinical trials for metastatic breast cancer. This late-stage asset, combined with other mid-stage programs like TACTI-002 and TACTI-003 for HNSCC and NSCLC, provides multiple potential value inflection points. The company's strategy of pursuing both oncology and autoimmune disease indications, exemplified by IMP761 and IMP731, diversifies its long-term growth potential. Strategic collaborations with major pharmaceutical companies such as GlaxoSmithKline, Novartis, and Merck & Co., Inc. validate its scientific approach and provide potential pathways for future development and commercialization funding. While current financial metrics show significant negative profit and gross margins, typical for a clinical-stage biotechnology company with a market capitalization of $66.17M, these are expected as substantial investment is directed towards R&D. The successful progression of its clinical assets through regulatory milestones and potential partnership expansions are key catalysts for future valuation, offering a focused opportunity for investors tracking novel immunotherapy developments.

Based on FMP financials and quantitative analysis

IMMP Key Highlights

• Market Capitalization of $66.17M, reflecting its status as a clinical-stage biotechnology company with significant R&D focus.
• Profit Margin of -1404.1% and Gross Margin of -522.6%, indicative of substantial investment in research and development and the absence of significant product revenue.
• Beta of 2.36, suggesting higher volatility compared to the broader market, which is common for biotechnology stocks with pipeline-driven valuations.
• Lead product candidate, eftilagimod alpha, is in Phase IIb clinical trial for metastatic breast cancer, representing a key advanced-stage asset.
• No dividend yield, consistent with a growth-oriented biotechnology company reinvesting all capital into pipeline development.

Who Are IMMP's Competitors?

IMMP is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are IMMP's Key Strengths?

• Advanced clinical pipeline with lead candidate eftilagimod alpha in Phase IIb for metastatic breast cancer.
• Diverse pipeline addressing both oncology and autoimmune diseases, offering multiple growth avenues.
• Strong network of collaboration agreements with major pharmaceutical companies like GlaxoSmithKline and Merck & Co., Inc.
• Specialized focus on immunotherapeutic products, a high-growth area in healthcare.
• Experienced management team (Marc Voigt) leading a dedicated R&D workforce of 41 employees.

What Are IMMP's Weaknesses?

• Significant negative profit margin (-1404.1%) and gross margin (-522.6%), indicative of high R&D costs and no substantial product revenue.
• Reliance on successful clinical trial outcomes, which are inherently uncertain and lengthy.
• Small market capitalization ($0.08B) makes the company susceptible to market volatility and limited access to capital compared to larger peers.
• High beta (2.36) suggests significant share price volatility, posing higher risk for investors.
• No current dividend yield, meaning no immediate return for shareholders outside of capital appreciation.

What Could Drive IMMP Stock Higher?

• Release of further clinical data from the Phase IIb TACTI-003 trial for head and neck squamous cell carcinoma, expected to provide insights into efti's efficacy in this indication.
• Progression of eftilagimod alpha (efti) from Phase IIb to Phase III clinical trials for metastatic breast cancer, signaling a significant advancement in its development pathway.
• Continued enrollment and data collection for the Phase II TACTI-002 trial in non-small cell lung cancer and HNSCC, with potential for interim data updates.
• Updates on the early-stage INSIGHT-003, INSIGHT-004, and INSIGHT-005 trials for solid tumors, which could provide initial indications of efficacy and safety for future development.
• Potential for expansion or new collaboration agreements with pharmaceutical partners based on positive clinical data, which could provide additional funding and validation.

What Are the Key Risks for IMMP?

• Financial-distress signal — its Altman Z-Score of -5.71 sits in the distress zone (elevated bankruptcy risk).
• Negative return on equity (-69.2%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures or unexpected adverse events in ongoing or future trials for eftilagimod alpha, TACTI-002, TACTI-003, or other pipeline candidates, which could halt development.
• Significant negative profit and gross margins (-1404.1% and -522.6% respectively) indicate a reliance on continuous funding for R&D, posing a risk if capital cannot be raised efficiently.
• Intense competition within the biotechnology sector for immunotherapies, potentially limiting market share even if products are successfully developed and approved.
• Regulatory delays or failure to obtain necessary approvals from health authorities for its product candidates, extending development timelines and increasing costs.
• Dependence on collaboration partners for funding, expertise, and commercialization, meaning any changes in partner strategies could negatively impact Immutep's programs.

What Are the Growth Opportunities for IMMP?

• **Advancement of Eftilagimod Alpha in Metastatic Breast Cancer:** Immutep's lead product candidate, eftilagimod alpha (efti), is currently in a Phase IIb clinical trial as a chemoimmunotherapy combination for metastatic breast cancer. The global market for breast cancer therapeutics is substantial, with estimates often exceeding tens of billions of dollars annually, and a significant portion dedicated to advanced stages. Successful progression through this trial and subsequent phases could unlock a major market opportunity, potentially leading to regulatory approval and commercialization. The timeline for such development typically spans several years, with Phase III trials and regulatory submissions following positive Phase IIb results. This asset represents a critical value driver due to its advanced clinical stage and potential to address an area of high unmet medical need.
• **Expansion of TACTI-002 and TACTI-003 Programs:** The TACTI-002 program is in Phase II clinical trials for head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC), while TACTI-003 is in Phase IIb for HNSCC. Both HNSCC and NSCLC represent large oncology markets, with NSCLC alone being one of the largest cancer indications globally, valued at over $20 billion annually. Positive results from these trials could significantly broaden Immutep's market reach in oncology. These programs are expected to continue through their respective clinical stages over the next few years, with data readouts serving as important catalysts. The competitive advantage lies in the potential efficacy and safety profile of efti in combination therapies, offering new treatment options for these challenging cancers.
• **Development of Early-Stage Solid Tumor Programs:** Immutep's pipeline includes early-stage programs like INSIGHT-004, INSIGHT-003, and INSIGHT-005, which are in Phase I or Phase I/IIa clinical trials for various solid tumors. While these are earlier in development, they represent future growth opportunities by exploring efti's potential across a wider spectrum of cancers. The total addressable market for solid tumors is vast and continuously expanding with new diagnostic and treatment modalities. These programs provide a long-term pipeline, with potential for significant value creation if early clinical data demonstrates promising efficacy and safety. The timeline for these programs to reach later stages is typically 5-10 years, but successful early data can attract further investment and partnerships.
• **Advancement of Autoimmune Disease Pipeline:** Beyond oncology, Immutep is developing immunotherapeutic products for autoimmune diseases, including IMP761 (an agonist of LAG-3) and IMP731 (a depleting antibody). The global market for autoimmune disease treatments is substantial and growing, driven by an increasing prevalence of conditions like rheumatoid arthritis, psoriasis, and inflammatory bowel disease. These programs diversify Immutep's therapeutic focus and reduce reliance solely on oncology outcomes. Successful preclinical and early clinical development in this area could open up entirely new market segments for the company. The competitive advantage here would be novel mechanisms of action for treating chronic autoimmune conditions, potentially offering better efficacy or safety profiles than existing therapies.
• **Leveraging Strategic Collaboration Agreements:** Immutep has established collaboration agreements with major pharmaceutical companies such as GlaxoSmithKline, Novartis, Merck & Co., Inc., and Merck KGaA. These partnerships are crucial for a clinical-stage biotech, providing access to funding, research expertise, manufacturing capabilities, and global commercialization networks. These collaborations validate Immutep's technology and pipeline, and successful progression of partnered programs could lead to milestone payments, royalties, and expanded agreements. The ongoing nature of these collaborations ensures continuous external validation and potential for shared development costs, significantly de-risking the development process and accelerating market access for its innovative therapies.

What Opportunities Does IMMP Have?

• Successful progression of eftilagimod alpha through Phase IIb and into Phase III trials for metastatic breast cancer, unlocking a major market.
• Positive data readouts from TACTI-002 and TACTI-003 trials in HNSCC and NSCLC, expanding oncology market penetration.
• Expansion of existing collaboration agreements or formation of new partnerships for pipeline assets, providing additional funding and expertise.
• Successful development of autoimmune disease candidates (IMP761, IMP731) to diversify therapeutic focus and market access.
• Potential for accelerated approval pathways or breakthrough therapy designations for highly effective immunotherapies.

What Threats Does IMMP Face?

• Clinical trial failures or unexpected adverse events, leading to delays or discontinuation of product candidates.
• Intense competition from other biotechnology and pharmaceutical companies developing similar immunotherapies.
• Regulatory hurdles and delays in obtaining approvals from health authorities.
• Patent expirations or challenges to intellectual property, eroding competitive advantage.
• Inability to secure sufficient funding for ongoing and future research and development activities.

What Are IMMP's Competitive Advantages?

• Proprietary clinical-stage pipeline, particularly eftilagimod alpha (LAG-3 agonist), which is a novel mechanism in immunotherapy.
• Extensive intellectual property surrounding its product candidates and their therapeutic applications.
• Strategic collaboration agreements with major pharmaceutical companies (e.g., GlaxoSmithKline, Novartis, Merck & Co., Inc.), validating its technology and providing development resources.
• Expertise in immunology and oncology research, cultivated since its incorporation in 1987, contributing to a specialized R&D capability.
• Diversified pipeline addressing both oncology and autoimmune diseases, reducing reliance on a single therapeutic area.

What Does IMMP Do?

Immutep Limited, incorporated in 1987 and based in Sydney, Australia, is a clinical-stage biotechnology company dedicated to the research and development of novel immunotherapeutic product candidates. The company's strategic focus lies in addressing significant unmet medical needs in both cancer and autoimmune diseases. Initially known as Prima BioMed Ltd, the company rebranded to Immutep Limited in November 2017, marking an evolution in its corporate identity and strategic direction. At the core of its pipeline is eftilagimod alpha (efti or IMP321), a recombinant protein currently undergoing a Phase IIb clinical trial as a chemoimmunotherapy combination for metastatic breast cancer, representing a key late-stage asset. Beyond this, Immutep is actively advancing several other programs, including TACTI-002, which is in a Phase II clinical trial for head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer, and TACTI-003, also in Phase IIb for HNSCC. The company's early-stage oncology pipeline includes INSIGHT-004, INSIGHT-003, and INSIGHT-005, all in Phase I or Phase I/IIa clinical trials for various solid tumors, indicating a broad approach to cancer treatment. Furthermore, Immutep is exploring therapeutic avenues for autoimmune diseases with candidates like IMP761, an agonist of lymphocyte activation gene 3, and IMP731, a depleting antibody. The company's development efforts are significantly bolstered by a network of collaboration agreements with prominent pharmaceutical entities such as GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma, underscoring its ability to attract and maintain strategic partnerships within the highly competitive biotechnology landscape.

What Products and Services Does IMMP Offer?

• Research and develop immunotherapeutic product candidates for cancer and autoimmune diseases.
• Advance eftilagimod alpha (efti or IMP321) through clinical trials, including Phase IIb for metastatic breast cancer.
• Conduct Phase II clinical trials for TACTI-002 in head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC).
• Manage Phase IIb clinical trials for TACTI-003 to treat HNSCC.
• Explore early-stage clinical trials (Phase I/IIa) for INSIGHT-003, INSIGHT-004, and INSIGHT-005 in solid tumors.
• Develop IMP761 for autoimmune diseases as an agonist of lymphocyte activation gene 3.
• Develop IMP731, a depleting antibody, to remove T cells involved in autoimmunity.
• Engage in collaboration agreements with major pharmaceutical companies for product development and potential commercialization.

How Does IMMP Make Money?

• Primarily generates revenue through research and development activities, often funded by capital raises and collaboration agreements.
• Aims to generate future revenue through milestone payments and royalties from licensing agreements with larger pharmaceutical partners upon successful clinical development and regulatory approval of its product candidates.
• Potential for direct product sales upon successful commercialization of its proprietary immunotherapies, though this is a long-term prospect.
• Focuses on creating intellectual property around novel immunotherapeutic mechanisms and compounds to drive long-term value.

What Industry Does IMMP Operate In?

Immutep Limited operates within the highly dynamic and innovation-driven biotechnology industry, a segment of the broader healthcare sector. This industry is characterized by extensive research and development efforts, long product development cycles, and significant regulatory hurdles. The global biotechnology market is projected to continue its robust growth, driven by advancements in genomics, personalized medicine, and immunotherapies. Immutep's focus on immunotherapeutic products for cancer and autoimmune diseases positions it within a particularly competitive and high-potential sub-segment. The company competes with numerous pharmaceutical and biotechnology firms, both large and small, that are also developing novel treatments in these therapeutic areas. Its strategy involves leveraging its unique product candidates, such as eftilagimod alpha, and forging strategic collaborations to carve out a niche and accelerate development within this landscape. The success of companies in this industry is heavily reliant on clinical trial outcomes, intellectual property, and strategic partnerships.

Who Are IMMP's Key Customers?

• Ultimately, patients suffering from various cancers, including metastatic breast cancer, head and neck squamous cell carcinoma, non-small cell lung cancer, and other solid tumors.
• Patients with autoimmune diseases who could benefit from novel immunomodulatory therapies.
• Pharmaceutical and biotechnology companies seeking to license or partner on innovative immunotherapeutic assets to expand their own pipelines.
• Medical professionals and healthcare systems seeking advanced treatment options for challenging diseases.

ROE -69%Key Financial Metrics

Return on equity for Immutep Limited stands at -69.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -57.0%, showing how much profit it generates from its asset base. Its free cash flow yield is -74.1%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.97 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -100.1%, the inverse of the P/E and a quick read on earnings relative to price.

Immutep Limited (IMMP) Valuation Context

Valued at $66.17M, IMMP is classified as a micro-cap stock. Relative to its peer group, IMMP's quantitative score of 58/100 is below the peer average of 76/100.

Company Profile

Immutep Limited operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Sydney, AU. The company is led by CEO Marc Voigt. IMMP has traded publicly since 2012.

F-Score 3/9Financial Health

Immutep Limited's Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -5.71 places it in the distress zone, a signal of elevated financial risk.

FY2026 estForward Outlook

Wall Street analysts project Immutep Limited revenue of about $9.2M for fiscal 2026, with EPS near $-0.27. The estimate reflects 3 contributing analysts.

IMMP Financials

IMMP Latest News

IMMP Analyst Consensus

IMMP MoonshotScore

Latest Immutep Limited Analysis

What Investors Ask About Immutep Limited (IMMP) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources